Literature DB >> 28534538

Prostate cancer: Better VISTAs ahead? Potential and pitfalls of immunotherapy.

Ravi A Madan1, James L Gulley1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28534538      PMCID: PMC6628252          DOI: 10.1038/nrurol.2017.75

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN: 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  9 in total

1.  Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial.

Authors:  Eugene D Kwon; Charles G Drake; Howard I Scher; Karim Fizazi; Alberto Bossi; Alfons J M van den Eertwegh; Michael Krainer; Nadine Houede; Ricardo Santos; Hakim Mahammedi; Siobhan Ng; Michele Maio; Fabio A Franke; Santhanam Sundar; Neeraj Agarwal; Andries M Bergman; Tudor E Ciuleanu; Ernesto Korbenfeld; Lisa Sengeløv; Steinbjorn Hansen; Christopher Logothetis; Tomasz M Beer; M Brent McHenry; Paul Gagnier; David Liu; Winald R Gerritsen
Journal:  Lancet Oncol       Date:  2014-05-13       Impact factor: 41.316

2.  VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer.

Authors:  Jianjun Gao; John F Ward; Curtis A Pettaway; Lewis Z Shi; Sumit K Subudhi; Luis M Vence; Hao Zhao; Jianfeng Chen; Hong Chen; Eleni Efstathiou; Patricia Troncoso; James P Allison; Christopher J Logothetis; Ignacio I Wistuba; Manuel A Sepulveda; Jingjing Sun; Jennifer Wargo; Jorge Blando; Padmanee Sharma
Journal:  Nat Med       Date:  2017-03-27       Impact factor: 53.440

3.  Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

Authors:  Philip W Kantoff; Celestia S Higano; Neal D Shore; E Roy Berger; Eric J Small; David F Penson; Charles H Redfern; Anna C Ferrari; Robert Dreicer; Robert B Sims; Yi Xu; Mark W Frohlich; Paul F Schellhammer
Journal:  N Engl J Med       Date:  2010-07-29       Impact factor: 91.245

4.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

Authors:  James Larkin; Vanna Chiarion-Sileni; Rene Gonzalez; Jean Jacques Grob; C Lance Cowey; Christopher D Lao; Dirk Schadendorf; Reinhard Dummer; Michael Smylie; Piotr Rutkowski; Pier F Ferrucci; Andrew Hill; John Wagstaff; Matteo S Carlino; John B Haanen; Michele Maio; Ivan Marquez-Rodas; Grant A McArthur; Paolo A Ascierto; Georgina V Long; Margaret K Callahan; Michael A Postow; Kenneth Grossmann; Mario Sznol; Brigitte Dreno; Lars Bastholt; Arvin Yang; Linda M Rollin; Christine Horak; F Stephen Hodi; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2015-05-31       Impact factor: 91.245

5.  Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.

Authors:  Tomasz M Beer; Eugene D Kwon; Charles G Drake; Karim Fizazi; Christopher Logothetis; Gwenaelle Gravis; Vinod Ganju; Jonathan Polikoff; Fred Saad; Piotr Humanski; Josep M Piulats; Pablo Gonzalez Mella; Siobhan S Ng; Dirk Jaeger; Francis X Parnis; Fabio A Franke; Javier Puente; Roman Carvajal; Lisa Sengeløv; M Brent McHenry; Arvind Varma; Alfonsus J van den Eertwegh; Winald Gerritsen
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

Review 6.  Immunoregulatory functions of VISTA.

Authors:  Elizabeth C Nowak; J Louise Lines; Frederick S Varn; Jie Deng; Aurelien Sarde; Rodwell Mabaera; Anna Kuta; Isabelle Le Mercier; Chao Cheng; Randolph J Noelle
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

7.  Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.

Authors:  Joseph L Benci; Bihui Xu; Yu Qiu; Tony J Wu; Hannah Dada; Christina Twyman-Saint Victor; Lisa Cucolo; David S M Lee; Kristen E Pauken; Alexander C Huang; Tara C Gangadhar; Ravi K Amaravadi; Lynn M Schuchter; Michael D Feldman; Hemant Ishwaran; Robert H Vonderheide; Amit Maity; E John Wherry; Andy J Minn
Journal:  Cell       Date:  2016-12-01       Impact factor: 41.582

8.  Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer.

Authors:  Lawrence Fong; Peter Carroll; Vivian Weinberg; Stephen Chan; Jera Lewis; John Corman; Christopher L Amling; Robert A Stephenson; Jeffrey Simko; Nadeem A Sheikh; Robert B Sims; Mark W Frohlich; Eric J Small
Journal:  J Natl Cancer Inst       Date:  2014-09-24       Impact factor: 13.506

9.  Early evidence of anti-PD-1 activity in enzalutamide-resistant prostate cancer.

Authors:  Julie N Graff; Joshi J Alumkal; Charles G Drake; George V Thomas; William L Redmond; Mohammad Farhad; Jeremy P Cetnar; Frederick S Ey; Raymond C Bergan; Rachel Slottke; Tomasz M Beer
Journal:  Oncotarget       Date:  2016-08-16
  9 in total
  2 in total

Review 1.  Potentiating prostate cancer immunotherapy with oncolytic viruses.

Authors:  Patrick Lee; Shashi Gujar
Journal:  Nat Rev Urol       Date:  2018-02-13       Impact factor: 14.432

2.  SNAP25 is a potential prognostic biomarker for prostate cancer.

Authors:  Longjiang Di; Maoli Gu; Yan Wu; Guoqiang Liu; Lishuo Zhang; Yifei Li; Wenjing Zhang
Journal:  Cancer Cell Int       Date:  2022-04-07       Impact factor: 5.722

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.